kinetic-ensemble
(2)
Ensem Therapeutics
Ensem Therapeutics is a Waltham, Massachusetts clinical-stage biotech using its Kinetic Ensemble platform - a blend of AI/ML, molecular simulation, and experimental biophysics - to find cryptic and allosteric pockets in proteins that are otherwise considered difficult to drug. The company designs small-molecule precision medicines for cancer, with two lead programs: ETX-636, an allosteric pan-mutant-selective PI3Kalpha inhibitor and degrader for breast cancer (FDA Fast Track), and ETX-197/BG-68501, a selective CDK2 inhibitor partnered with BeiGene.
Shengfang Jin
Shengfang Jin is a co-founder and the President and CEO of Ensem Therapeutics, a Waltham, Massachusetts biotech developing small-molecule cancer drugs by targeting protein pockets that only exist while the protein is in motion. Under Jin, Ensem built its Kinetic Ensemble platform, took its first CDK2 inhibitor into the clinic, and its ETX-636 breast cancer program earned FDA Fast Track designation. She trained at Tufts and Harvard, spent years at Agios helping deliver first-in-class cancer metabolism drugs, and then ran discovery biology at Editas before starting Ensem.